Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Menorrhagia 5 mg bid-tid from the 19th -26th day of cycle (count the 1st day of menstruation as day 1). Endometriosis 10-20 mg daily starting between 1st and 5th day of the cycle, continuously for 4-6 months. As norethisterone acetate: 5-15 mg daily, start at 5 mg daily and increase by 2.5 mg at 14-day intervals; take continuously for 6-9 months. Contraception 0.35 mg daily. Premenstrual syndrome 5 mg tid on days 19-26 of the cycle. Dysfunctional uterine bleeding 5 mg tid for 10 days; 5 mg bid from the 19th-26th day of the 2 subsequent cycles to prevent recurrence of the condition. As norethisterone acetate: 2.5-10 mg daily for 5-10 days. Postponement of menstruation 5 mg tid for up to 14 days starting 3 days before expected onset of menstruation. Dysmenorrhoea 5 mg tid for 20 days, starting on the 5th day of the cycle (count the 1st day of menstruation as day 1). IM Contraception As norethisterone enantate: 200 mg given within first 5 days of menstrual cycle every 8 weeks.
May be taken with or without food.
Known, suspected, or history of breast cancer or endometrial cancer, active or recent arterial thromboembolic disease (e.g. stroke, MI), current or history of venous thromboembolism (e.g. DVT, pulmonary embolism), angina pectoris, undiagnosed vaginal bleeding, porphyria, benign or malignant hepatic tumour; severe diabetes with vascular changes, pathologically increased blood pressure (as norethisterone enantate). Hepatic impairment or disease (e.g. Dubin-Johnson syndrome, Rotor syndrome). Pregnancy.
Special Precautions
Patient with risk factors for cardiovascular disease (e.g. hypercholesterolaemia, hypertension, obesity), and/or venous thromboembolism (e.g. personal or family history of venous thromboembolism, SLE, prolonged immobilisation); depression, diabetes mellitus, conditions that may be aggravated by fluid retention (e.g. asthma, migraine, epilepsy, cardiac dysfunction). Smokers. Renal impairment. Lactation. Monitoring Parameters Assess pregnancy status prior to therapy, diagnostic measures (e.g. endometrial sampling). Monitor weight, vision changes (e.g. loss of vision, diplopia), signs or symptoms of depression, glycaemic control (in diabetic patients), lipid profile (patients treated for hyperlipidaemia). Perform breast and pelvic examination (e.g. Papanicolaou smear), as necessary.
Adverse Reactions
Significant: As contraceptive: Irregular menstrual bleeding, breast cancer, visual abnormalities (e.g. partial or complete loss of vision, proptosis, diplopia), migraine, depression, decreased glucose tolerance, venous thromboembolism (e.g. deep vein thrombosis). Rarely, benign or malignant liver tumour. Gastrointestinal disorders: Nausea, vomiting, abdominal pain. General disorders and administration site conditions: Fatigue. Hepatobiliary disorders: Cholestatic jaundice. Immune system disorders: Hypersensitivity. Investigations: Weight gain, abnormal LFT. Metabolism and nutrition disorders: Oedema. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Insomnia. Reproductive system and breast disorders: Breast tenderness, amenorrhoea, spotting, decreased libido, change in cervical secretions, cervical erosion, breast hypertrophy. Skin and subcutaneous tissue disorders: Acne, chloasma, pruritus, urticaria.
Drug Interactions
Decreased therapeutic effect with barbiturates, phenytoin, carbamazepine, griseofulvin, felbamate. Increased plasma concentrations with CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, verapamil, diltiazem). May reduce the therapeutic effect of ulipristal.
ATC Classification
G03DC02 - norethisterone ; Belongs to the class of estren derivative progestogens used in progestogenic hormone preparations.
G03AC01 - norethisterone ; Belongs to the class of progestogens. Used as systemic contraceptives.
Disclaimer: This information is independently developed by CIMS based on norethisterone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in